
Kurt Alfred Jaeckle MD
Breast Cancer, Neuro-Oncology
Professor of Neurology and Oncology Consultant Mayo Clinic Florida
Join to View Full Profile
4500 San Pablo Road SJacksonville, FL 32224
Dr. Jaeckle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
 - Connect with colleagues in the same hospital or clinic.
 - Read the latest clinical news, personalized to your specialty.
 
Summary
- Kurt A. Jaeckle, M.D., is currently Professor of Neurology and Professor of Oncology at the Mayo Clinic Florida in Jacksonville .
Dr. Jaeckle received his MD from Indiana University School of Medicine, Internship in Medicine and Residency in Neurology at Vanderbilt University in Nashville, TN; and Fellowship in Neuro-oncology at Memorial Sloan Kettering Cancer Center. Dr. Jaeckle is Board Certified in Neurology by the ABPN and in Neuro-oncology by the UCNS. He was an Associate Professor of Neurology at the University of Utah Health Sciences Center; Associate Professor and Deputy Chairman of Neurology at the University of Texas MD Anderson Cancer Center; Medical Director of Research for the Atlantic Health System, and Professor of Neurology and Oncology at the Mayo Clinic.
Dr. Jaeckle has served as an investigator on several national and international Phase I-III clinical trials, and has authored multiple peer-reviewed papers involving primary and metastatic brain tumors and neurologic complications of cancer. He has served on committees for the American Academy of Neurology, Society for Neurooncology, the National Institutes of Health, and National Cancer Institute. He served as Director of the Neurooncology Fellowship Program at MD Anderson Cancer Center, and was instrumental in development of the Certification and Accreditation in Neurooncology for the UCNS.
Dr. Jaeckle’s clinical practice and research focuses on targeted treatments, immunotherapy, vaccines, chemotherapy for patients with primary and metastatic CNS neoplasms.
Dr. Jaeckle enjoys spending time with his wife, Bunny Leach-Jaeckle, supporting her efforts as a patient advocate for ASCO, for the Alliance for Clinical Trials in Oncology, and for Mayo Clinic; and, as Director and CEO of the Nicki Leach Foundation, a non-profit organization supporting cancer research involving adolescents and young adults. He is also a luthier, who builds and repairs acoustic and electric guitars. 
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1981 - 1983
Vanderbilt University Medical CenterFellowship, Neuromuscular Medicine (Neurology), 1980 - 1981
Vanderbilt University Medical CenterResidency, Neurology, 1977 - 1981
Vanderbilt University Medical CenterInternship, Internal Medicine, 1977 - 1978
Indiana University School of MedicineClass of 1977
Certifications & Licensure
GA State Medical License 2014 - 2027
FL State Medical License 2000 - 2026
NJ State Medical License 2016 - 2019
KY State Medical License 2014 - 2017
UT State Medical License 1983 - 2004
TX State Medical License 1993 - 2002
American Board of Psychiatry and Neurology Neurology- United Council of Neurologic SubspecialtiesNeuro-oncology
 
Clinical Trials
- Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
 - Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Start of enrollment: 2000 Jun 01
 - Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme Start of enrollment: 2002 Jul 01
 - Join now to see all
 
Publications & Presentations
PubMed
- Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 ...James J Harding, Do-Youn Oh, Teresa Macarulla Mercade, Lipika Goyal, Andreas Varkaris
Clinical Cancer Research. 2025-09-30 - Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas.Mohamed F Ali, Cecile Riviere-Cazaux, Sarah H Johnson, Rebecca Salvatori, Alan R Penheiter
Clinical Cancer Research. 2025-05-01 - 5 citationsEfficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini
JAMA Oncology. 2024-12-01 
Journal Articles
- Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal LymphomaLisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood
 - Diffuse Midline Gliomas with Subclonal H3F3A K27M Mutation and Mosaic H3.3 K27M Mutant Protein ExpressionKurt Jaeckle, Yaron A Moshel, Arie Perry, David A Solomon, Acta Neuropathologica
 
Press Mentions
Finding Joy After Rare Neurologic DiagnosisOctober 14th, 2021
Dr. Kurt Jaeckle to Lead Phase III Clinical Trial of Novel Drug VAL-083 for Late-Stage GlioblastomaJanuary 10th, 2018
Risks of Whole Brain Radiation Therapy Added to Radiosurgery Outweigh Benefits for Patients with Limited Brain MetastasesMay 31st, 2015
Professional Memberships
- Member
 - Fellow
 - Member
 - Society for Neuro-oncologyMember
 
External Links
- Nicki Leach Foundationhttp://www.nickileach.org
 - Prism Guitarshttp://www.prismguitars.com
 - Atlantic Health Systemhttp://www.atlantichealth.org
 
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









